Arrivent Biopharma Inc expected to post a loss of 66 cents a share - Earnings Preview

ArriVent BioPharma

05/05/2025 12:33

Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 66 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00​, above​ its last closing price of $21.30. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.78
-0.78
-0.61
Beat
21.5
Sep. 30 2024
-0.72
-1.00
-0.61
Beat
39.1
Jun. 30 2024
-0.65
-0.64
-0.65
Missed
-1​
Mar. 31 2024
-1.09
-1.10
-0.70
Beat
36.2
​​
​

This summary was machine generated May 5 at 11:33 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)